Therefore, therapeutic strategies, based on manipulation of LRP5 or canonical Wnt signaling, may be effective in targeting both osteoporosis and retinal vascular defects in OPPG patients, with the retinal vasculature being more resistant to potential side effects. The gene discussed is LRP5; the disease is osteoporosis-pseudoglioma syndrome.